clinical trial · NCT01868997
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
Amgen·phase2·completed·n = 88
Thyroid Associated OphthalmopathiesThyroid-Associated Ophthalmopathyteprotumumabnormal saline
brief summary
The primary objective of this study is to investigate the efficacy, safety, and tolerability of RV 001 (teprotumumab), a fully human anti-IGF1R antibody, administered q3W for 6 months, in comparison to placebo, in the treatment of participants suffering from active TED. "Funding Source - FDA OOPD"
started
Jul 1, 2013
primary completion
Mar 1, 2016
completion
Feb 22, 2017
last updated
Dec 17, 2024
detailed description
Study with completed results acquired from Horizon in 2024.
official title
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol